natgillin/translations-raw huggingface dataset:
A compound of formula or a pharmaceutically acceptable salt, ester or amide thereof, wherein the pharmaceutically acceptable ester is selected from C1-C8 alkyl esters, C5-C7 cycloalkyl esters and arylalkyl esters and the pharmaceutically acceptable amide is selected from amides derived from ammonia, primary C1-C8 alkyl amines, secondary C1-C8 dialkyl amines and secondary amines in the form of a 5- or 6-membered heterocycloalkyl group containing at least one nitrogen atom, for use in a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective dosage amount of the compound, or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from 
Spoj formule, ili njegova farmaceutski prihvatljiva sol, ester ili amid, pri čemu je farmaceutski prihvatljiv ester odabran od C1-C8 alkil estera, C5-C7 cikloalkil estera i arilalkil estera i farmaceutski prihvatljiv amid je odabran od amida dobivenih od amonijaka, primarnih C1-C8 alkil amina, sekundarnih C1-C8 dialkil amina i sekundarnih amina u obliku 5- ili 6-člane heterocikloalkilne grupe koja sadrži barem jedan atom dušika, za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno, gdje postupak sadrži primjenjivanje na subjektu djelotvorne dozne količine spoja, ili njegove farmaceutski prihvatljive soli, pri čemu je rak odabran od
carcinomas, which comprise cancer of the bladder, breast, colon, rectum, kidney, liver, lung, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin; 
karcinoma, koji sadrže rak mjehura, dojke, debelog crijeva, rektuma, bubrega, jetre, pluća, jednjaka, žučnog mjehura, jajnika, gušterače, želuca, cerviksa, štitnjače, prostate, i kože;
tumors of mesenchymal origin, which comprise fibrosarcoma and rhabdomyosarcoma, and other sarcomas, which comprise soft tissue sarcomas and bone sarcomas; 
tumora mezenhimalnog porijekla, koji sadrže fibrosarkom i rabdomiosarkom, i druge sarkome, koji sadrže sarkome mekog tkiva i sarkome kostiju;
tumors of the central and peripheral nervous system, which comprise astrocytoma, neuroblastoma, glioma and schwannomas; 
tumora centralnog i perifernog živčanog sustava, koji sadrže astrocitom, neuroblastom, gliom i schwanome;
melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, Kaposi's sarcoma, endometrial cancer, head and neck cancer, glioblastoma, malignant ascites, or hematopoietic cancers. 
melanoma, seminoma, teratokarcinoma, osteosarkoma, xenoderoma pigmentosum, keratoktantoma, folikularnog karcinoma štitnjače, Kaposijevog sarkoma, raka endometrija, raka glave i vrata, glioblastoma, malignog ascitesa, ili hematopoetskih rakova.
The compound for use in a method of treating cancer in a subject in need thereof of claim 5, wherein the cancer is a hematopoietic tumor of lymphoid lineage. 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema zahtjevu 5, pri čemu je rak hematopoetski tumor limfoidne loze.
The compound for use in a method of treating cancer in a subject in need thereof of claim 5, wherein the cancer is soft tissue sarcoma. 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema zahtjevu 5, pri čemu je rak sarkom mekog tkiva.
The compound for use in a method of treating cancer in a subject in need thereof of claim 5, wherein the cancer is breast cancer. 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema zahtjevu 5, pri čemu je rak rak dojke.
The compound for use in a method of treating cancer in a subject in need thereof of claim 5, wherein the cancer is glioblastoma. 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema zahtjevu 5, pri čemu je rak glioblastom.
The compound for use in a method of treating cancer in a subject in need thereof of claim 5, wherein the cancer is acute myeleogenous leukemia (AML). 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema zahtjevu 5, pri čemu je rak akutna mijelogena leukemija (AML).
The compound for use in a method of treating cancer in a subject in need thereof of claim 5, wherein the cancer is melanoma. 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema zahtjevu 5, pri čemu je rak melanom.
The compound for use in a method of treating cancer in a subject in need thereof of claim 5, wherein the cancer is myelodysplastic syndrome. 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema zahtjevu 5, pri čemu je rak mijelodisplastični sindrom.
The compound for use in a method of treating cancer in a subject in need thereof of any one of claims 5-12, wherein the cancer is identified as p53wildtype (p53WT). 
Spoj za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno prema bilo kojem od zahtjeva 5-12, pri čemu je rak identificiran kao divlji tip p53 (p53WT).
A medicament comprising the compound as depicted in claim 1 for use in a method of treating cancer in a subject in need thereof. 
Lijek koji sadrži spoj koji je opisan u zahtjevu 1 za uporabu u postupku liječenja raka kod subjekta kojemu je ono potrebno.
The medicament for use of claim 14 or 15, wherein the medicament is to be used in combination with radiation therapy. 
Lijek za uporabu prema zahtjevu 14 ili 15, pri čemu se lijek koristi u kombinaciji s radioterapijom.
A pharmaceutical composition comprising the ester, amide or prodrug of the compound according to claim 17. 
Farmaceutski sastav koji sadrži ester, amid ili prolijek spoja prema zahtjevu 17.
said anti-HERV-W Env ligand is an antibody, more particularly a chimeric, engineered or humanized antibody, and even more particularly an IgG, such as an IgG1 or an IgG4, wherein said antibody comprises each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 
navedeni anti-HERV-W Env ligand je antitijelo, točnije kimerno, projektirano ili humanizirano antitijelo, i još točnije IgG, poput IgG1 ili IgG4, pri čemu navedeno antitijelo sadrži svaku od regija koje određuju komplementarnost (CDR) navedenih u SEQ ID No.
said Nitric Oxyde radical inhibitory drug is selected from the group consisting of Ng-nitro-L-arginine-methylester (L-NAME), S-methyl-isothiourea (SMT) and dimethyl fumarate (DMF). 
navedeni inhibitorni lijek radikala dušikovog oksida je odabran iz skupine koja se sastoji od Ng-nitro-L-arginin-metilestera (L-NAME), S-metil-izotioureje (SMT) i dimetil fumarata (DMF).
A pharmaceutical product containing: 
Farmaceutski proizvod koji sadrži:
as a combination product for simultaneous, separate or spread over time administration for use in preventing and/or treating the remyelination blockage in a disease associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype, wherein: 
kao kombinacijski proizvod za istodobnu, odvojenu ili primjenu raširenu tijekom vremena za uporabu u sprječavanju i/ili liječenju remijelinizacijske blokade u bolesti koja je povezana s ekspresijom HERV-W proteina ovojnice (ENV), posebice njegovog MSRV podtipa, naznačen time što:
said Nitric Oxyde radical inhibitory drug is selected from the group consisting of Ng-nitro-L-arginine-methylester (L-NAME), S-methyl-isothiourea (SMT) and dimethyl fumarate (DMF), and 
navedeni inhibitorni lijek radikala dušikovog oksida je odabran iz skupine koja se sastoji od Ng-nitro-L-arginin-metilestera (L-NAME), S-metil-izotioureje (SMT) i dimetil fumarata (DMF) i
the first first domain VLA and the fourth domain VHA is specific for CD3; 
prva domena VLA i četvrta domena VHA su specifične za CD3;
the second domain VHB of the first polypeptide chain is in association with the third domain VLB of the second polypeptide chain to form an antigen binding site specific for the tumor cell; 
druga domena VHB prvog polipeptidnog lanca je povezana s trećom domenom VLB drugog polipeptidnog lanca da bi se oblikovalo antigen-vezujuće mjesto specifično za tumorsku stanicu;
A nucleic acid molecule encoding the polypeptide chain of the dimeric antigen-binding molecule according to anyone of claims 1 to 6. 
Molekula nukleinske kiseline koja kodira polipeptidni lanac dimerne antigen-vezujuće molekule prema bilo kojem od patentnih zahtjeva 1 do 6.
The antigen-binding molecule for use according to claim 11, wherein the B-cell malignancy is selected from the group consisting of lymphoblastic leukemia and non-Hodgkin's lymphoma. 
Antigen-vezujuća molekula za upotrebu prema patentnom zahtjevu 11, naznačena time, što je malignitet B-stanica izabran iz grupe koja se sastoji od limfoblastne leukemije i ne-Hodgkinovog limfoma.
A process for the preparation of a compound of formula I wherein said process comprises reacting a compound of formula II with one or more suitable Vilsmeier reagent. 
Postupak za pripremu spoja formule I pri čemu spomenuti postupak obuhvaća reakciju spoja formule II s jednim ili više odgovarajućim Vilsmeier-ovim reagensom.
reacting the compound of formula II to form a compound of formula IV and subsequently 
reakcije spoja formule II zbog formiranja spoja formule IV i zatim
the process is performed as a one-pot process and/or without isolation of a compound of formula IV and/or; 
se postupak izvodi kao postupak u jednom reaktoru i/ili bez izoliranja spoja formule IV i/ili;
the process comprises the further step of isolating and optionally purifying the compound of formula I. 
postupak dalje obuhvaća korak izoliranja i opcionalno pročišćavanja spoja formule I.
A process for the preparation of a compound of formula V wherein the process comprises reacting a compound of formula I as defined in Claim 1 with a suitable reducing agent. 
Postupak za pripremu spoja formule V pri čemu postupak obuhvaća reakciju spoja formule I kao što je definirano u zahtjevu 1 s odgovarajućim reducensom.
the process comprises the further step of isolating and optionally purifying the compound of formula V and/or; 
postupak obuhvaća korak izoliranja i opcionalno pročišćavanja spoja formule V i/ili;
the compound of formula V is isolated as and/or purified via the formation of a bisulfite adduct of formula VI wherein Z represents an alkali metal. 
spoj formule V se izolira kao i/ili pročišćava putem formiranja bisulfitnog adukta formule VI pri čemu Z predstavlja alkalni metal.
A process for preparing a compound of formula VI as defined in Claim 9, wherein the process comprises reacting a compound of formula V as defined in Claim 6 with a compound having the formula ZHSO3, wherein Z is as defined in the compound of formula VI. 
Postupak za pripremu spoja formule VI prema zahtjevu 9, pri čemu postupak obuhvaća reakciju spoja formule V kao što je definirano u zahtjevu 6 sa spojem koji ima formulu ZHSO3, pri čemu je Z kao što je definirano u spoju formule VI.
A process for the preparation of compound of formula VII or a suitable salt thereof, wherein the process comprises the steps of: 
Postupak za pripremu spoja formule VII ili njegove odgovarajuće soli, pri čemu postupak obuhvaća korake:
preparing a compound of formula V using a process as defined in any one of Claims 6 to 9; 
pripreme spoja formule V upotrebom postupka kao što je definirano u bilo kojem od zahtjeva 6 do 9;
reacting the compound of formula V to form a compound of formula VIII wherein L1 represents a suitable leaving group; and 
reakcije spoja formule V zbog formiranja spoja formule VIII pri čemu L1 predstavlja odgovarajuću odlazeću grupu; i
formamide, to form the compound of formula VII, or a suitable salt thereof. 
formamida, kako bi se tvorio spoj formule VII, ili njegova odgovarajuća sol.
A process as claimed in Claim 13 or Claim 14, wherein the process comprises the further step of isolating and optionally purifying the compound of formula VIII. 
Postupak prema zahtjevu 13 ili zahtjevu 14, pri čemu postupak dalje obuhvaća korake izoliranja i opcionalno pročišćavanja spoja formule VIII.
The low dose pharmaceutical composition for use in treating inflammatory bowel disease according to any of the preceding claims is for non-parenteral administration. 
Niskodozni farmaceutski preparat, za upotrebu u liječenju inflamatorne crijevne bolesti prema bilo kom od prethodnih patentnih zahtjeva je za ne-parenteralnu primjenu.
The compound for use of claim 6 wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier selected from diluent, binder, disintegrant, pH adjusting agent and lubricant. 
Jedinjenje za upotrebu prema patentnom zahtjevu 6, naznačeno time, da farmaceutski preparat dalje sadrži najmanje jedan farmaceutski prihvatljiv nosač odabran od sredstva za razblaživanje, vezivnog sredstva, sredstva za dezintegraciju, sredstva za podešavanje pH i lubrikansa.
An anti-CD 154 antibody or a CD 154-binding fragment thereof, comprising: 
Protutijelo protiv CD154, ili njegov CD154-vežući fragment, naznačeno time što sadrži:
The anti-CD 154 antibody or the CD 154-binding fragment thereof according to claims 1-4, wherein: 
Protutijelo protiv CD154, ili njegov CD154-vežući fragment, u skladu s patentnih zahtjeva 1-4, naznačeno time što:
the anti-CD 154 antibody is an antigen-binding fragment of an anti-CD 154 antibody, and said antigen-binding fragment is selected from the group consisting of Fab, F(ab)2, Fab', F(ab')2, F(ab')3, Fd, and Fv. 
protutijelo protiv CD154 je antigenski vežući fragment protutijela protiv CD154, a navedeni antigenski vežući fragment se bira iz skupine koju čine Fab, F(ab)2, Fab’, F(ab’)2, F(ab’)3, Fd, te Fv.
The anti-CD 154 antibody or the CD 154-binding fragment thereof according to claim 6, wherein the CD 154 antibody is a Fab' fragment wherein a thiol group in a modified hinge region is covalently linked to a maleimide group that is covalently linked to a lysine residue, wherein a methoxypoly(ethyleneglycol) polymer having a molecular weight of approximately 20,000 Da is attached to each of the amine groups of the lysine. 
Protutijelo protiv CD154, ili njegov CD154-vežući fragment, u skladu s patentnim zahtjevom 6, naznačeno time što je protutijelo protiv CD154 Fab’ fragment, gdje je tiolna skupina u modificiranom području zgloba kovalentno vezana na maleimidnu skupinu koja je kovalentno vezana na lizinski ostatak, gdje je metoksipoli(etilen-glikol)ni polimer koji ima molekulsku težinu od otprilike 20.000 Da vezan na svaku od aminskih skupina u lizinu.
The anti-CD 154 antibody or the CD 154-binding fragment thereof according to claim 1, wherein: 
Protutijelo protiv CD154, ili njegov CD154-vežući fragment, u skladu s patentnim zahtjevom 1, naznačeno time što:
the antibody or the fragment thereof lacks an immunoglobulin Fc region; or 
protutijelu, ili njegovom fragmentu, nedostaje Fc područje u imunoglobulinu; ili
The anti-CD 154 antibody or the CD 154-binding fragment thereof according to claim 1, wherein the antibody or the fragment thereof further comprises a variant Fc region that is a hybrid Fc region comprising sequences from more than one Ig Fc domain type. 
Protutijelo protiv CD154, ili njegov CD154-vežući fragment, u skladu s patentnim zahtjevom 1, naznačen time što protutijelo, ili njegov fragment, dodatno sadrži varijanta Fc područja koje je hibridno Fc područje koje sadrži sljedove iz više od jedne domene Ig Fc tipa.
A nucleic acid molecule encoding the anti-CD 154 antibody or the CD 154-binding fragment thereof according to any one of claims 1-12. 
Molekula nukleinske kiseline, naznačena time što kodira protutijelo protiv CD154, ili njegov CD154-vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1-12.
culturing a host cell according to claim 16 under conditions suitable for expression of the anti-CD 154 antibody or the CD 154-binding fragment thereof, by said host cell; and 
uzgoja stanice domaćina u skladu s patentnim zahtjevom 16 u uvjetima pogodnim za eksprimiranje protutijela protiv CD154, ili njegovog CD154-vežućeg fragmenta, od strane navedene stanice domaćina; i
A composition comprising the anti-CD 154 antibody or the CD 154-binding fragment thereof according to any one of claims 1-12 and a suitable pharmaceutical carrier. 
Pripravak, naznačen time što sadrži protutijelo protiv CD154, ili njegov CD154-vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1-12, kao i pogodnu farmaceutsku podlogu.
The use according to claim 21, wherein the inflammatory or autoimmune response or fibrosis is selected from rheumatoid arthritis, systemic lupus erythematosus, spondylarthritis, inflammatory bowel disease, Crohn's disease, psoriasis, scleroderma, lupus nephritis, idiopathic thrombocytopenia purpura, vascular disease and multiple sclerosis. 
Upotreba u skladu s patentnim zahtjevom 21, naznačena time što se upalni ili autoimuni odgovor ili fibrozu bira između reumatoidnog artritisa, sistemni eritematoznog lupusa, spondilartritisa, upalne crijevne bolesti, Crohnove bolesti, psorijaze, skleroderme, lupusnog nefritisa, idiopatske trombocitopenične purpure, bolesti krvnih žila i multiple skleroze.
The composition for use according to claim 1, wherein the composition comprises sodium phosphate buffer, optionally wherein the composition comprises 5 mM to 50 mM sodium phosphate, 10 mM to 30 mM sodium phosphate, or 20 mM sodium phosphate. 
Pripravak za uporabu prema zahtjevu 1, naznačen time što pripravak sadrži natrijev fosfatni pufer, proizvoljno pri čemu pripravak sadrži 5 mM do 50 mM natrijevog fosfata, 10 mM do 30 mM natrijevog fosfata, ili 20 mM natrijevog fosfata.
The composition for use according to any one of the preceding claims, wherein the subject is administered a high initial dose of the at least one C1 esterase inhibitor, followed by lower maintenance doses, optionally wherein the high initial dose is at least 1.5, 2, 3, 4, or 5 times the subsequent doses, and/or the high initial dose is administered intravenously and the at least one C1 esterase inhibitor is subsequently administered subcutaneously. 
Pripravak za uporabu prema bilo kojem prethodnom zahtjevu, naznačen time što se subjektu daje visoka početna doza najmanje jednog inhibitora C1 esteraze, nakon čega slijede manje doze za održavanje, pri čemu je po potrebi visoka početna doza najmanje 1,5, 2, 3, 4, ili 5 puta naknadnih doza, i/ili se visoka početna doza daje intravenski i najmanje jedan inhibitor C1 esteraze se nakon toga daje potkožno.
The composition for use according to any preceding claim, wherein the administration of the at least one C1 esterase inhibitor leads to increased levels of the C1 esterase inhibitor in the blood of the subject, wherein the blood levels of the C1 esterase inhibitor are increased to at least 0.3 U/mL, 0.4 U/mL, or up to 1 U/mL. 
Pripravak za uporabu prema bilo kojem prethodnom zahtjevu, naznačen time što davanje najmanje jednog inhibitora C1 esteraze dovodi do povećanih razina inhibitora C1 esteraze u krvi subjekta, pri čemu su razine inhibitora C1 esteraze u krvi povećane do najmanje 0,3 U/mL, 0,4 U/mL, ili do 1 U/mL.
comprises at least one amino acid or salt thereof; and/or 
sadrži najmanje jednu aminokiselinu ili njezinu sol; i/ili
or R1 and R2, taken together with the intervening atoms, form a carbocyclic or heterocyclic ring; 
ili R1 i R2, uzeti zajedno s atomima među njima, tvore karbociklički ili heterociklički prsten;
R6, taken together with the carbon atom bearing it, represents -C(O)-; 
, zajedno s ugljikovim atomom koji ga nosi, predstavlja -C(O)-;
or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, or polymorph thereof. 
ili njegova farmaceutski prihvatljiva sol, solvat, tautomer, stereoizomer ili polimorf.
The compound of claim 24 or 25, wherein R2 is -C(O)heterocyclyl selected from the group consisting of 
Spoj prema zahtjevu 24 ili 25, naznačen time što je R2 -C(O)heterociklil odabran iz skupine koju čine
A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 1-54; and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak naznačen time što sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva 1-54; te farmaceutski prihvatljiv nosač.
The pharmaceutical composition of claim 55, further comprising a therapeutically effective amount of a therapeutic agent selected from the group consisting of steroids, membrane stabilizers, 5LO inhibitors, leukotriene synthesis and receptor inhibitors, inhibitors of IgE isotype switching or IgE synthesis, IgG isotype switching or IgG synthesis, β-agonists, tryptase inhibitors, acetylosalicylic acid, COX inhibitors, methotrexate, anti-TNF drugs, rituxin and other B-cell targeting agents, THF-targeting agents, PD4 inhibitors, p38 inhibitors, PDE4 inhibitors, and antihistamines. 
Farmaceutski pripravak prema zahtjevu 55, naznačen time što nadalje sadrži terapeutski učinkovitu količinu terapeutskog sredstva odabranog iz skupine koju čine steroidi, membranski stabilizatori, inhibitori 5LO, inhibitori sinteze i receptori leukotriena i receptor, inhibitori zamjene izotipa IgE ili sinteze IgE, inhibitori zamjene izotipa IgG ili sinteze IgG, β-agonisti, inhibitori triptaze, acetilosalicilna kiselina, inhibitori COX, metotreksat, anti-TNF lijekovi, rituksin i druga sredstva za ciljanje B-stanica, sredstva za ciljanje THF, inhibitori PD4, inhibitori p38, inhibitori PDE4 i antihistaminici.
Compounds for use of claim 61, wherein the disease, disorder, or condition is an allergic disease selected from the group consisting of asthma, allergic rhinitis, seasonal allergic rhinitis, chronic rhinosinusitis with or without nasal polyps, conjunctivitis, keratoconjunctivitis, seasonal allergic conjunctivitis, dry eye syndrome, eosinophilic esophagitis, celiac disease, food allergy, irritable bowel syndrome, irritable bowel disease, atopic eczema, atopic dermatitis, allergic contact dermatitis, eosinophilic otitis media, eosinophilic pneumonia, and IgG4 mediated diseases. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest, poremećaj ili stanje alergijska bolest odabrana iz skupine koju čine astma, alergijski rinitis, sezonski alergijski rinitis, kronični rinosinusitis s ili bez nosnih polipa, konjunktivitis, keratokonjunktivitis, sezonski alergijski konjunktivitis, sindrom suhog oka, eozinofilni ezofagitis, celijakija, alergija na hranu, sindrom iritabilnog crijeva, iritabilna bolest crijeva, atopijski ekcem, atopijski dermatitis, alergijski kontaktni dermatitis, eozinofilni otitis media, eozinofilna upala pluća i bolesti posredovane s IgG4.
Compounds for use of claim 61, wherein the disease, disorder, or condition is an acute or chronic inflammatory disease selected from the group consisting of fungal diseases, parasitic infections, celiac disease, microscopic colitis, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, interstitial lung diseases, cystic fibrosis, Hermansky-Pudlak syndrome, and Alzheimer's disease. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest, poremećaj ili stanje akutna ili kronična upalna bolest odabrana od skupina koju čine gljivične bolesti, parazitske infekcije, celijakija, mikroskopski kolitis, kronična opstruktivna plućna bolest (KOPB), idiopatska plućna fibroza, intersticijske plućne bolesti, cistična fibroza, Hermansky-Pudlakov sindrom i Alzheimerova bolest.
Compounds for use of claim 61, wherein the disease, disorder, or condition is an autoimmune disorder selected from the group consisting of inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, osteoarthritis, psoriasis, scleroderma, multiple sclerosis, Sjögren's syndrome, atherosclerosis, and sarcoidosis. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest, poremećaj ili stanje autoimuni poremećaj odabran iz skupine koju čine upalna bolest crijeva, ulcerozni kolitis, Crohnova bolest, reumatoidni artritis, osteoartritis, psorijaza, sklerodermija, multipla skleroza, Sjögrenov sindrom, ateroskleroza i sarkoidoza.
Compounds for use of claim 61, wherein the disease, disorder, or condition is periodontitis. 
Spojevi za uporabu prema zahtjevu 61, naznačeni time što je bolest, poremećaj ili stanje periodontitis.